Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)

Elizabeth Needham Waddell; Sandra A. Springer; Lisa A. Marsch; David Farabee; Robert P. Schwartz; Amesika Nyaku; Rusty Reeves; Keith Goldfeld; Ryan D. McDonald; Mia Malone; Anna Cheng; Elizabeth C. Saunders; Laura Monico; Jan Gryczynski; Kathleen Bell; Kasey Harding; Sandra Violette; Thomas Groblewski; Wendy Martin; Kasey Talon; Nicole Beckwith; Andrew Suchocki; Randy Torralva; Jennifer P. Wisdom; Joshua D. Lee

doi:10.1016/j.jsat.2021.108389

Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)

Elizabeth Needham Waddell, Sandra A. Springer, Lisa A. Marsch, David Farabee, Robert P. Schwartz, Amesika Nyaku, Rusty Reeves, Keith Goldfeld, Ryan D. McDonald, Mia Malone, Anna Cheng, Elizabeth C. Saunders, Laura Monico, Jan Gryczynski, Kathleen Bell, Kasey Harding, Sandra Violette, Thomas Groblewski, Wendy Martin, Kasey TalonNicole Beckwith, Andrew Suchocki, Randy Torralva, Jennifer P. Wisdom, Joshua D. Lee

School Of Public Health

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

The EXIT-CJS (N = 1005) multisite open-label randomized controlled trial will compare retention and effectiveness of extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder (OUD) among criminal justice system (CJS)-involved adults in six U.S. locales (New Jersey, New York City, Delaware, Oregon, Connecticut, and New Hampshire). With a pragmatic, noninferiority design, this study hypothesizes that XR-B (n = 335) will be noninferior to XR-NTX (n = 335) in retention-in-study-medication treatment (the primary outcome), self-reported opioid use, opioid-positive urine samples, opioid overdose events, and CJS recidivism. In addition, persons with OUD not eligible or interested in the RCT will be recruited into an enhanced treatment as usual arm (n = 335) to examine usual care outcomes in a quasi-experimental observational cohort.

Original language	English (US)
Article number	108389
Journal	Journal of Substance Abuse Treatment
Volume	128
DOIs	https://doi.org/10.1016/j.jsat.2021.108389
State	Published - Sep 2021

Keywords

Buprenorphine
Criminal justice
Injection
Medication treatment
Naltrexone
Opioid use disorder

ASJC Scopus subject areas

Phychiatric Mental Health
Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

Access to Document

10.1016/j.jsat.2021.108389

Cite this

Waddell, E. N., Springer, S. A., Marsch, L. A., Farabee, D., Schwartz, R. P., Nyaku, A., Reeves, R., Goldfeld, K., McDonald, R. D., Malone, M., Cheng, A., Saunders, E. C., Monico, L., Gryczynski, J., Bell, K., Harding, K., Violette, S., Groblewski, T., Martin, W., ... Lee, J. D. (2021). Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal of Substance Abuse Treatment, 128, Article 108389. https://doi.org/10.1016/j.jsat.2021.108389

Waddell, EN, Springer, SA, Marsch, LA, Farabee, D, Schwartz, RP, Nyaku, A, Reeves, R, Goldfeld, K, McDonald, RD, Malone, M, Cheng, A, Saunders, EC, Monico, L, Gryczynski, J, Bell, K, Harding, K, Violette, S, Groblewski, T, Martin, W, Talon, K, Beckwith, N, Suchocki, A, Torralva, R, Wisdom, JP & Lee, JD 2021, 'Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)', Journal of Substance Abuse Treatment, vol. 128, 108389. https://doi.org/10.1016/j.jsat.2021.108389

@article{979adaa5982b449380d73858b7abfa65,

title = "Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)",

abstract = "The EXIT-CJS (N = 1005) multisite open-label randomized controlled trial will compare retention and effectiveness of extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder (OUD) among criminal justice system (CJS)-involved adults in six U.S. locales (New Jersey, New York City, Delaware, Oregon, Connecticut, and New Hampshire). With a pragmatic, noninferiority design, this study hypothesizes that XR-B (n = 335) will be noninferior to XR-NTX (n = 335) in retention-in-study-medication treatment (the primary outcome), self-reported opioid use, opioid-positive urine samples, opioid overdose events, and CJS recidivism. In addition, persons with OUD not eligible or interested in the RCT will be recruited into an enhanced treatment as usual arm (n = 335) to examine usual care outcomes in a quasi-experimental observational cohort.",

keywords = "Buprenorphine, Criminal justice, Injection, Medication treatment, Naltrexone, Opioid use disorder",

author = "Waddell, {Elizabeth Needham} and Springer, {Sandra A.} and Marsch, {Lisa A.} and David Farabee and Schwartz, {Robert P.} and Amesika Nyaku and Rusty Reeves and Keith Goldfeld and McDonald, {Ryan D.} and Mia Malone and Anna Cheng and Saunders, {Elizabeth C.} and Laura Monico and Jan Gryczynski and Kathleen Bell and Kasey Harding and Sandra Violette and Thomas Groblewski and Wendy Martin and Kasey Talon and Nicole Beckwith and Andrew Suchocki and Randy Torralva and Wisdom, {Jennifer P.} and Lee, {Joshua D.}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = sep,

doi = "10.1016/j.jsat.2021.108389",

language = "English (US)",

volume = "128",

journal = "Journal of Substance Abuse Treatment",

issn = "0740-5472",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)

AU - Waddell, Elizabeth Needham

AU - Springer, Sandra A.

AU - Marsch, Lisa A.

AU - Farabee, David

AU - Schwartz, Robert P.

AU - Nyaku, Amesika

AU - Reeves, Rusty

AU - Goldfeld, Keith

AU - McDonald, Ryan D.

AU - Malone, Mia

AU - Cheng, Anna

AU - Saunders, Elizabeth C.

AU - Monico, Laura

AU - Gryczynski, Jan

AU - Bell, Kathleen

AU - Harding, Kasey

AU - Violette, Sandra

AU - Groblewski, Thomas

AU - Martin, Wendy

AU - Talon, Kasey

AU - Beckwith, Nicole

AU - Suchocki, Andrew

AU - Torralva, Randy

AU - Wisdom, Jennifer P.

AU - Lee, Joshua D.

PY - 2021/9

Y1 - 2021/9

N2 - The EXIT-CJS (N = 1005) multisite open-label randomized controlled trial will compare retention and effectiveness of extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder (OUD) among criminal justice system (CJS)-involved adults in six U.S. locales (New Jersey, New York City, Delaware, Oregon, Connecticut, and New Hampshire). With a pragmatic, noninferiority design, this study hypothesizes that XR-B (n = 335) will be noninferior to XR-NTX (n = 335) in retention-in-study-medication treatment (the primary outcome), self-reported opioid use, opioid-positive urine samples, opioid overdose events, and CJS recidivism. In addition, persons with OUD not eligible or interested in the RCT will be recruited into an enhanced treatment as usual arm (n = 335) to examine usual care outcomes in a quasi-experimental observational cohort.

AB - The EXIT-CJS (N = 1005) multisite open-label randomized controlled trial will compare retention and effectiveness of extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder (OUD) among criminal justice system (CJS)-involved adults in six U.S. locales (New Jersey, New York City, Delaware, Oregon, Connecticut, and New Hampshire). With a pragmatic, noninferiority design, this study hypothesizes that XR-B (n = 335) will be noninferior to XR-NTX (n = 335) in retention-in-study-medication treatment (the primary outcome), self-reported opioid use, opioid-positive urine samples, opioid overdose events, and CJS recidivism. In addition, persons with OUD not eligible or interested in the RCT will be recruited into an enhanced treatment as usual arm (n = 335) to examine usual care outcomes in a quasi-experimental observational cohort.

KW - Buprenorphine

KW - Criminal justice

KW - Injection

KW - Medication treatment

KW - Naltrexone

KW - Opioid use disorder

UR - http://www.scopus.com/inward/record.url?scp=85104111535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104111535&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2021.108389

DO - 10.1016/j.jsat.2021.108389

M3 - Article

C2 - 33865691

AN - SCOPUS:85104111535

SN - 0740-5472

VL - 128

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

M1 - 108389

ER -

Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this